$NMTC Dave Rosa, CEO of NeuroOne commented, "We are excited with the results of our initial long-term testing of recording capabilities for our thin film electrode technology. These results support the potential expansion of utilization of these electrodes for long-term recording for indications such as epilepsy, Parkinson's disease, chronic back pain due to failed back surgeries, other related neurological disorders as well as research applications. We also believe that in the near term it may provide an opportunity to enter the research market as well as offering the potential for strategic licensing agreements in certain markets."
https://finance.yahoo.com/news/neuroone-medic...00500.html